TW202045175A - Ｓｕｍｏ-活化酶抑制劑及檢查點抑制劑之投與 - Google Patents

Ｓｕｍｏ-活化酶抑制劑及檢查點抑制劑之投與 Download PDF

Info

Publication number
TW202045175A
TW202045175A TW109106512A TW109106512A TW202045175A TW 202045175 A TW202045175 A TW 202045175A TW 109106512 A TW109106512 A TW 109106512A TW 109106512 A TW109106512 A TW 109106512A TW 202045175 A TW202045175 A TW 202045175A
Authority
TW
Taiwan
Prior art keywords
day
administered
cancer
administration
antibody
Prior art date
Application number
TW109106512A
Other languages
English (en)
Chinese (zh)
Inventor
賽 木拉里 克里斯那 普魯庫利
Original Assignee
美商千禧製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商千禧製藥公司 filed Critical 美商千禧製藥公司
Publication of TW202045175A publication Critical patent/TW202045175A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109106512A 2019-02-27 2020-02-27 Ｓｕｍｏ-活化酶抑制劑及檢查點抑制劑之投與 TW202045175A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962811303P 2019-02-27 2019-02-27
US62/811,303 2019-02-27

Publications (1)

Publication Number Publication Date
TW202045175A true TW202045175A (zh) 2020-12-16

Family

ID=72238984

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109106512A TW202045175A (zh) 2019-02-27 2020-02-27 Ｓｕｍｏ-活化酶抑制劑及檢查點抑制劑之投與

Country Status (11)

Country Link
US (1) US12419890B2 (https=)
EP (1) EP3930719B1 (https=)
JP (1) JP7539896B2 (https=)
KR (1) KR20210131316A (https=)
CN (1) CN113473989B (https=)
AU (1) AU2020228385A1 (https=)
BR (1) BR112021016795A8 (https=)
CA (1) CA3128521A1 (https=)
MX (1) MX2021010176A (https=)
TW (1) TW202045175A (https=)
WO (1) WO2020176772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021000349A (es) 2018-07-09 2021-05-14 Takeda Pharmaceuticals Co Administracion de un inhibidor de la enzima activadora de sumo y anticuerpos anti-cd20.
CA3128521A1 (en) 2019-02-27 2020-09-03 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
BRPI0516132A (pt) 2004-10-07 2007-12-04 Vitae Pharmaceuticals Inc compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
ES2542884T3 (es) * 2008-09-23 2015-08-12 Rigel Pharmaceuticals, Inc. Inhibidores de JAK de carbamato tricíclico
WO2010044892A1 (en) 2008-10-17 2010-04-22 President And Fellows Of Harvard College Diagnostic method based on large scale identification of post-translational modification of proteins
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2012159782A1 (en) 2011-05-24 2012-11-29 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High affinity sumo traps
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
TWI874834B (zh) * 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
NZ738406A (en) * 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
US20190054090A1 (en) * 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
WO2018154529A1 (en) 2017-02-27 2018-08-30 Novartis Ag Dosing schedule for a combination of ceritinib and an anti-pd-1 antibody molecule
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CA3128521A1 (en) 2019-02-27 2020-09-03 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

Also Published As

Publication number Publication date
US20220233531A1 (en) 2022-07-28
CN113473989A (zh) 2021-10-01
AU2020228385A1 (en) 2021-07-29
BR112021016795A8 (pt) 2022-08-16
CN113473989B (zh) 2024-03-08
US12419890B2 (en) 2025-09-23
CA3128521A1 (en) 2020-09-03
JP7539896B2 (ja) 2024-08-26
BR112021016795A2 (pt) 2021-10-19
JP2022522328A (ja) 2022-04-18
WO2020176772A1 (en) 2020-09-03
KR20210131316A (ko) 2021-11-02
EP3930719B1 (en) 2025-08-20
EP3930719A4 (en) 2022-11-23
EP3930719A1 (en) 2022-01-05
MX2021010176A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
US12403154B2 (en) Administration of sting agonist and checkpoint inhibitors
JP7352582B2 (ja) Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
EP3930719B1 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
TW202233206A (zh) Ｓｔｉｎｇ促效劑、檢查點抑制劑及輻射之投與
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
TW202207935A (zh) Ｓｕｍｏ活化酶抑制劑及抗ｃｄ３８抗體之投與
WO2026053159A1 (en) Dazostinag or conjugates thereof for treatment of adenoid cystic carcinomas
WO2021088853A1 (zh) 喹啉衍生物与pd-1单抗的药物组合